Literature DB >> 25225290

A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.

Tameka A Bailey1, Haitao Luan2, Eric Tom3, Timothy Alan Bielecki1, Bhopal Mohapatra3, Gulzar Ahmad1, Manju George1, David L Kelly4, Amarnath Natarajan4, Srikumar M Raja4, Vimla Band5, Hamid Band6.   

Abstract

ErbB2 overexpression drives oncogenesis in 20-30% cases of breast cancer. Oncogenic potential of ErbB2 is linked to inefficient endocytic traffic into lysosomes and preferential recycling. However, regulation of ErbB2 recycling is incompletely understood. We used a high-content immunofluorescence imaging-based kinase inhibitor screen on SKBR-3 breast cancer cells to identify kinases whose inhibition alters the clearance of cell surface ErbB2 induced by Hsp90 inhibitor 17-AAG. Less ErbB2 clearance was observed with broad-spectrum PKC inhibitor Ro 31-8220. A similar effect was observed with Go 6976, a selective inhibitor of classical Ca(2+)-dependent PKCs (α, β1, βII, and γ). PKC activation by PMA promoted surface ErbB2 clearance but without degradation, and ErbB2 was observed to move into a juxtanuclear compartment where it colocalized with PKC-α and PKC-δ together with the endocytic recycling regulator Arf6. PKC-α knockdown impaired the juxtanuclear localization of ErbB2. ErbB2 transit to the recycling compartment was also impaired upon PKC-δ knockdown. PMA-induced Erk phosphorylation was reduced by ErbB2 inhibitor lapatinib, as well as by knockdown of PKC-δ but not that of PKC-α. Our results suggest that activation of PKC-α and -δ mediates a novel positive feedback loop by promoting ErbB2 entry into the endocytic recycling compartment, consistent with reported positive roles for these PKCs in ErbB2-mediated tumorigenesis. As the endocytic recycling compartment/pericentrion has emerged as a PKC-dependent signaling hub for G-protein-coupled receptors, our findings raise the possibility that oncogenesis by ErbB2 involves previously unexplored PKC-dependent endosomal signaling.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Breast Cancer; Confocal Microscopy; Endocytic Traffic; Endocytosis; ErbB2; High-Content Fluorescence Microscopy; Kinase Inhibitors; Protein Kinase C (PKC); Receptor Tyrosine Kinase; Small Molecule Screening

Mesh:

Substances:

Year:  2014        PMID: 25225290      PMCID: PMC4215227          DOI: 10.1074/jbc.M114.608992

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  115 in total

1.  The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C.

Authors:  Z Han; P Pantazis; T S Lange; J H Wyche; E A Hendrickson
Journal:  Cell Death Differ       Date:  2000-06       Impact factor: 15.828

Review 2.  Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.

Authors:  Len Neckers
Journal:  Curr Med Chem       Date:  2003-05       Impact factor: 4.530

3.  Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.

Authors:  S E Winograd-Katz; A Levitzki
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

4.  Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination.

Authors:  Páris N M Sidiropoulos; Michaela Miehe; Thomas Bock; Elisa Tinelli; Carole I Oertli; Rohini Kuner; Dies Meijer; Bernd Wollscheid; Axel Niemann; Ueli Suter
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

Review 5.  Regulation of MAPKs by growth factors and receptor tyrosine kinases.

Authors:  Menachem Katz; Ido Amit; Yosef Yarden
Journal:  Biochim Biophys Acta       Date:  2007-01-10

6.  c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.

Authors:  Richard Marcotte; Lixin Zhou; Harold Kim; Calvin D Roskelly; William J Muller
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

Review 7.  HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

Authors:  Christian Widakowich; Phuong Dinh; Evandro de Azambuja; Ahmad Awada; Martine Piccart-Gebhart
Journal:  Anticancer Agents Med Chem       Date:  2008-06       Impact factor: 2.505

8.  Suppression of epidermal growth factor receptor signaling by protein kinase C-alpha activation requires CD82, caveolin-1, and ganglioside.

Authors:  Xiao-qi Wang; Qiu Yan; Ping Sun; Ji-Wei Liu; Linda Go; Shauntae M McDaniel; Amy S Paller
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

9.  Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.

Authors:  Alessandra Magnifico; Luisa Albano; Stefano Campaner; Manuela Campiglio; Silvana Pilotti; Sylvie Ménard; Elda Tagliabue
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.

Authors:  Katia Cortese; Mark T Howes; Richard Lundmark; Erica Tagliatti; Paola Bagnato; Annalisa Petrelli; Maria Bono; Harvey T McMahon; Robert G Parton; Carlo Tacchetti
Journal:  Mol Biol Cell       Date:  2012-11-14       Impact factor: 4.138

View more
  18 in total

1.  Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.

Authors:  Jaekwang Jeong; Jungmin Choi; Wonnam Kim; Pamela Dann; Farzin Takyar; Julia V Gefter; Peter A Friedman; John J Wysolmerski
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

2.  PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.

Authors:  Kinnari Pandya; Debra Wyatt; Brian Gallagher; Deep Shah; Andrew Baker; Jeffrey Bloodworth; Andrei Zlobin; Antonio Pannuti; Andrew Green; Ian O Ellis; Aleksandra Filipovic; Jason Sagert; Ajay Rana; Kathy S Albain; Lucio Miele; Mitchell F Denning; Clodia Osipo
Journal:  Clin Cancer Res       Date:  2015-09-08       Impact factor: 12.531

Review 3.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

4.  Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.

Authors:  Daniela Castanotto; Min Lin; Claudia Kowolik; Troels Koch; Bo Rode Hansen; Henrik Oerum; Cy A Stein
Journal:  Mol Ther       Date:  2016-03-10       Impact factor: 11.454

5.  Inhibition of PKCα reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis.

Authors:  Bo Zhan; Chuize Kong; Zhe Zhang; Xiao Dong; Naiwen Zhang
Journal:  Exp Ther Med       Date:  2017-03-23       Impact factor: 2.447

6.  CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface.

Authors:  Luke R Cypher; Timothy Alan Bielecki; Lu Huang; Wei An; Fany Iseka; Haitao Luan; Eric Tom; Matthew D Storck; Adam D Hoppe; Vimla Band; Hamid Band
Journal:  Cell Signal       Date:  2016-05-17       Impact factor: 4.315

7.  Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion.

Authors:  Ditte Marie Brix; Siri Amanda Tvingsholm; Malene Bredahl Hansen; Knut Bundgaard Clemmensen; Tiina Ohman; Valentina Siino; Matteo Lambrughi; Klaus Hansen; Pietri Puustinen; Irina Gromova; Peter James; Elena Papaleo; Markku Varjosalo; José Moreira; Marja Jäättelä; Tuula Kallunki
Journal:  Oncogene       Date:  2019-01-08       Impact factor: 9.867

Review 8.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

9.  Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.

Authors:  Srikumar M Raja; Swapnil S Desale; Bhopal Mohapatra; Haitao Luan; Kruti Soni; Jinjin Zhang; Matthew A Storck; Dan Feng; Timothy A Bielecki; Vimla Band; Samuel M Cohen; Tatiana K Bronich; Hamid Band
Journal:  Oncotarget       Date:  2016-03-01

10.  Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach.

Authors:  Fei Yuan; Yu-Hang Zhang; Sibao Wan; ShaoPeng Wang; Xiang-Yin Kong
Journal:  Biomed Res Int       Date:  2015-11-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.